[1] Abeliovich, D., Kaduri, L., Lerer, I., et al. "The founder mutations 185delAG and 5382insC in BRCA1  and 6174delT in BRCA2 ap-pear in 60% of ovarian cancer and 30% of early-onset breast cancer patients  among Ashkenazi women", Am J. Hum Genet, Vol. 60, pp. 505-514. (1997).

[2] Ah Mew, N., Hamel, N., Galvez, M., Al-Saffar, M., Foulkes, "W. D. Haplotype analysis of a BRCA1:0   185delAG mutation in a Chilean family supports its Ashkenazi origins",Clin Genet, Vol. 62, pp. 151-156. (2002).

[3] Andersen, T. I., Borresen, A. L., Moller, P. A. "A common BRCA1 mutation in Norwegian breast and ovarian cancer families?", Amer. J. Hum. Genet. Vol. 59,  No. 2, pp. 486-487. (1996).

[4] Anglian Breast Cancer Study Group. "Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases", Anglian Breast Cancer Study Group. Br J. Cancer, Vol. 83, pp. 1301–1308. (2000).

[5] Antoniou, A., Pharoah, P. D., Narod, S., et al."Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies", Am J. Hum Genet, Vol. 72, pp. 1117–1130. (2003).

[6] Arason, A., Jonasdottir, A., Barkardottir, R. B., et al."A population study of muta-tions and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland", J. Med Genet,Vol. 35, pp. 446-449. (1998).

[7] Atour, M. F. and Al-Kayed, S. A. "Mutation analysis of the breast cancer gene BRCA1 among breast cancer Jordanian females", Saudi Med J., Vol. 25, No. 1, pp. 60-63. (2004).

[8] Bar-Sade, R. B., Kruglikova, A., Modan, B., et al."The 185delAG BRCA1 mutation originated before the dispersion of Jews in the Diaspora and is not limited to Ashkenazim", Hum Mol Genet, Vol. 7, pp. 801- 805. (1998).

[9] Brose, M. S., Rebbeck, T. R., Calzone, K. A., et al. "Cancer risk estimates for   BRCA1 mutation carriers identified in a risk evaluation program", J. Natl Cancer Inst., Vol. 94, pp. 1365-1372.( 2002).

[10]Burcos, T., Cimponeriu, D. , Ion, D. A., et al. "Analysis of several BRCA1 and BRCA2 mutations in a Hospital-based Series of unselected breast Cancer Cases", Chirurgia, Vol. 108, No. 4, pp. 468-472, (2013).

[11]Chan, P. C., Wong, B. Y., Ozcelik, H., Cole, D. E. "Simple and rapid de-tection of BRCA1 and BRCA2 mutations by multiplex mutage-netically separated PCR",ClinChem, Vol. 45.pp. 1285-1287. (1999).

[12]Chen, J. J., Silver, D., Cantor, S., Livingston, D. M., Scully, R. "BRCA1, BRCA2 and RAD51 operate in a common DNA damage response pathway",Cancer Res, Vol. 59, pp. 1752– 1756. (1999).

[13]Chen, P. L., Chen, C. F., Chen, Y., Xiao, J., Sharp, Z. D., Lee, W. H. "The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methane sulfonate treatment", Proc Nat AcadSci USA, Vol. 95, pp. 5287–5292. (1998).

[14]Collins, N., McManus, R., Wooster, R., et al. "Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13", Oncogene, Vol. 10, pp. 1673-1675, (1995).

[15]Cox, A., Dunning, A. M., Garcia-Closas, M., et al. "A common coding variant in CASP8 is associated with breast cancer risk", Nat Genet, Vol. 39, pp. 352–358. (2007).

[16]Couch, F. J., Deshano, M. L., Blackwood, M. A., et al."BRCA1mutations in women attending clinics that evaluate the risk of breast cancer", N. Engl J. Med, Vol. 336, pp. 1409 –1415. (1997).

[17]Diez, O., Domenech, M., Alonso, M. C., et al. "Identification of the 185delAG BRCA1 mutation in a Spanish Gypsy population", Hum Genet, Vol. 103, pp. 707-708. (1998).

[18]Diez, O., Osorio, A., Robledo, M., et al. "Prevalence of BRCA1 and BRCA2 Jewish mutations in  Spanish breast cancer patients", Br J Cancer, Vol. 79, pp. 1302-1303. (1999).

[19]Easton, D., McGuffog, L., Thompson, D., Dunning, A., Tee, L., et al."CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies", Am J Hum Genet,Vol. 74, pp. 1175–1182. (2004).

[20]El Gezeery, A., Mahmud, N., Moustafa, A., Mahrous, H., Mahmoud, H., Abd El-Menam, N. "BRCA1 gene mutation in familial breast cancer", Turkish J. Cancer, Vol. 38, pp. 167–174. (2008).

[21]FitzGerald, M. G., MacDonald, D. J., Krainer, M., et al. "Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer",N Engl J. Med.,Vol. 334, pp. 143 – 149. (1996).

[22]Ford, D., Easton, D. F., Stratton, M., et al."Genetic heterogeneity and penetrance analysis of the  BRCA1and BRCA2 genes in breast cancer families", The Breast Cancer Linkage Consortium. Am J. Hum Genet, Vol. 62, pp. 676–689. (1998).

[23]Friedman, L. S., Szabo, C. I., Ostermeyer, E. A., et al. "Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families", Am J Hum Genet, Vol. 57, pp. 284-297. (1995).

[24]Gowen, L. C., Johnson, B. L., Latour, A. M., Sulik, K. K., Koller, B. H. "Brca1ciency results in early        embryonic lethality characterized byneuroepithelial abnormalities", Nat Genet, Vol. 12, No. 2, pp. 191-194. (1996).

[25]Grzybowska, E., Siemińska, M., Zientek, H., et al. "Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population", ActaBiochim. Pol., Vol. 49, pp. 351–356. (2002).

[26]Guran, S., Ozet, A., Dede, M., Gille, J. J. and Yenen, M. C. "Hereditary breast cancer syndromes in a Turkish population. Results of molecular germline analysis", Cancer Genet.Cytogenet, Vol. 160, pp.164–168. (2005).

[27]Hakansson, S., Johannsson, O., Johannsson, U., et al. "Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer", Amer. J. Hum. Genet., Vol. 60, No. 5, pp. 1068-1078. (1996).

[28]Hall, J. M., Lee, M. K., Newman, B., et al. "Linkage of early-onset familial breast cancer to chromosome 17q21", Science, Vol. 250, pp. 1684–1689. (1990).

[29]Hartge, P., Struewing, J. P., Wacholder, S., Brody, L. C., Tucker, M. A. "The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews", Am. J.Hum Genet, Vol.64, pp.963-970, (1999).

[30]Huusko, P., Paakkonen, K., Launonen, V., et al. "Evidence of founder mutations in Finnish breast cancer families", Am J. Hum Genet, Vol. 62, pp. 1544-1548. (1998).

[31]Ikeda, N., Miyoshi, Y., Yoneda, K., et al. "Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families", Int. J. Cancer, Vol. 91, pp. 83–98. (2001).

[32]Janiszewska, H., Haus, O., Lauda-Swieciak, A., et al. "Frequency of three BRCA1 gene founder mutations in breast/ovarian cancer families from the Pomerania-Kujawy region of Poland",Clin Genet,Vol. 64, No. 6, pp. 502-508. (2003).

[33]Jara, L., Ampuero, S., Seccia, L., et al. "Frecuencia de la mutación 185delAG en el gen BRCA1 en mujereschilenas sanas con antecedentsfamiliares de cáncer de mama",Revmed Chile, Vol. 130, pp.1113-1123. (2002).

[34]Johannsson, O., Ostermeyer, E. A., Hakansson, S., et al. "Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden", Amer.J. Hum.Genet, Vol.58, No.3, pp 441–450, (1996). 

[35]Koifman, S., Jorge Koifman, R. "Breast cancer mortality among Ashkenazi Jewish women in São Paulo and Porto Alegre", Brazil. Breast Cancer Res., Vol. 3, No. 4, pp. 270-275. (2001).

[36]Levine, A. J. "The tumor suppressor genes",Annu Rev Biochem, Vol. 62, pp. 623-651. (1993).

[37]Levy-Lahad, E., Catane, R., Eisenberg, S., et al. "Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential pen-etrance in ovarian cancer and in breast-ovarian cancer  fam-ilies",Am J. Hum Genet, Vol. 60, pp. 1059 – 1067. (1997).

[38]Llort, G., Peris, M. and Blanco, I. "Hereditary breast and ovarian cancer: primary and secondary prevention for BRCA1 and BRCA2 mutation carriers", Med. Clin., Vol. 128, pp. 468-476. (2007).

[39]Lynch, H.T., Silva, E. Snyder, C., Lynch, J. F. "Hereditary breast cancer:   Part   I. diagnosing hereditary  breast  cancer syndromes",The B. J., Vol. 14, pp. 3–13. (2008).

[40]Mathew, A., Pandey, M., Rajan, B. "Do younger woman with non-metastatic and non-inflammatory breast carcinoma have poor prognosis?", World J SurgOncol, Vol. 2, No. 2., pp. 1-7. (2004).

[41]Mehdipour, P., Hosseini-Asl, S., Savabi-E, A., Habibi, L., Alvandi, E., Atri, M. "Low Frequency of  185delAG Founder Mutation of BRCA1 Gene in Iranian Breast Cancer Patients",  J Cancer Molecules,Vol. 2, pp. 123 – 127. (2006).

[42]Meuth, M. "The structure of mutation in mammalian cells", BiochimBiophysActa,Vol. 1032, pp. 1-17. (1990).

[43]Miki, Y., Swensen, J., Shattuck-Eidens, D., et al. "A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1", Science, Vol.266, pp. 66-71. (1994).

[44]Miki, Y., Swensen, J., Shattuck Eiden, D. and Futreal, P.A. "A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1", Science, Vol.266, pp. 66-71. (1997).

[45]Mullineaux, L. G., Castellano, T. M., Shaw, J., et al. "Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado", Cancer,Vol.98, pp. 597–602. (2003).

[46]Neuhausen, S., Gilewski, T., Norton, L., et al. "Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer", Nature Genet, Vol. 13, pp. 126–128. (1996).

[47]Neuhausen, S. L. "Founder populations and their uses for breast cancer genetics", Breast Cancer Res., Vol.2, No. 2, pp. 77-81. (2000).

[48]Neuhausen, S. L. and Marshall, C. J. "Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds", Cancer Res, Vol. 54, pp. 6069-6072. (1994).

[49]Osorio, A., Robledo, M., Albertos, J., et al. "Molecular analysis of the six most recurrent mutations in the BRCA1 gene in 87 Spanish breast/ovarian cancer families", Cancer Lett. Vol.123, pp 153-158, (1998).

[50]Parkin, D. M., Bray, F., Ferlay, J., Pisani, P. "Global Cancer Statistics 2002", Cancer J. Clin., Vol. 55, No. 2, pp. 74–108. (2005).

[51]Parvin, G. D., Sankaran, S. "The BRCA1 E3 ubiquitin ligase controls centrosome dynamics", Cell Cycle,Vol.5, pp. 1946–1950. (2006).

[52]Peelen, T., van Vliet, M., Petrij-Bosch, A., et al. "A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families",  Am J. Hum Genet, Vol. 60, pp. 1041-1049. (1997).

[53]Perrin-Vidoz, L., Sinilnikova, O. M., Stoppa-Lyonnet, D., Lenoir, G. M., Mazoyer, S. "The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons", Hum Mol Genet., Vol. 11, No. 23, pp. 2805-2814. (2002).

[54]Phelan, C. M., Borg, A., Cuny, M., et al. "Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters", Cancer Res, Vol. 58, pp. 1004 -1012. (1998).

[55]Pohlreich, P., Zikan, M., Stribrna, J., Kleibl, Z., Janatova, M., Kotlas, J. "High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area", Breast Cancer Res, Vol.7, No. 5, pp. 728-736. (2005).

[56]Polyak, K. "Breast cancer genes discovery". Web site   www.expertreviews.org.(2002).

[57]Rahman, N., Seal, S., Thompson, D., et al. "PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene", Nat Genet, Vol. 39, pp. 165–167. (2007).

[58]Ramus, S. J., Kote-Jarai, Z., Friedman, L. S., et al. "Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer", Am J Hum Genet., Vol.60, No. 5, pp. 1242-1246. (1997).

[59]Rashid, M. U., Zaidi, A., Torres, D., et al. "Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients", Int. J. Cancer, Vol. 119, pp. 2832–2839. (2006).

[60]Renwick, A., Thompson, D., Seal, S., et al. "ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles", Nat Genet, Vol. 38, pp. 873–875. (2006).

[61]Rio, P. G., Pernin, D., Bay, J. O., et al. "Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma",Int J Oncol, Vol. 13, pp. 849-853. (1998).

[62]Risch, H. A., McLaughlin, J. R., Cole, D. E., et al."Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer", Am J. Hum Genet, Vol. 68, pp. 700–710.( 2001).

[63]Roa, B. B., Boyd, A. A., Volcik, K., Richards, C. S. "Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2",Nat Genet., Vol.14, pp. 185 –187. (1996).

[64]Seal, S., Thompson, D., Renwick,  A., et al. "Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles", Nat Genet, Vol. 38, pp. 1239–1241. (2006).

[65]Shih, H. A., Couch, F. J., Nathanson, K. L., et al. "BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic", J. Clin. Oncol., Vol. 20, pp. 994–999. (2002).

[66]Simard, J., Tonin, P., Duroche,r F., et al. "Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families" Nat Genet., Vol. 8, No. 4, pp. 392-398. (1994).

[67]Smith, S. A., Easton, D. F., Evans, D. G. and Ponder, B. A. "Allele losses in the region 17q12-21 in  familial breast and ovarian cancer involve the wild-type chromosome",Nat Genet, Vol. 2, pp. 128-131. (1992).

[68]Stanbridge, E. J. "Human tumor suppressor genes",Annu Rev Genet, Vol. 24, pp. 615-657. (1990).

[69]Struewing, J. P., Abeliovich, D., Peretz, T., Avishai, N., Kaback, M. M., Collins, F. S. and Brody, L. C."The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals",Nat Genet, Vol. 11, pp. 198-200. (1995).

[70]Struewing, J. P., Hartge, P., Wacholder, S., et al. "The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews", N Engl J Med., Vol. 336, No. 20, pp. 1401-1408. (1997).

[71]Szabo, C. I., King, M. C. "Population genetics of BRCA1 and BRCA2",  Am J. Hum Genet, Vol.  60, pp. 1013-1020. (1997).

[72]Tavtigian, S. V., Thomas, A., Frank, T. S. and Skolnick, M. H. "The BRCA1 gene and its protein product: characterization, therapeutic and diagnostic implications",AdvOncol, Vol. 14, pp. 3–13. (1998).

[73]Tikhomirova, L., Sinicka, O., Smite, D., Eglitis, J., Hodgson, S. V., Stengrevics, A. "High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia",Fam Cancer., Vol.4, No.2, pp. 77-84. (2005).

[74]Trincado, P., Fardella, C., Mayerson, D., Montero, L., Obrien, A., Barrueto, K. and Gallegos, R."Prevalencia de la deleción 185AG del gen BRCA1   en mujereschilenas con cancer de mama", Rev Med Chile, Vol. 127, pp. 19-22. (1999).

[75]Vehmanen, P., Friedman, L. S., Eerola, H., et al. "Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes", Hum. Genet., Vol.6, No. 13, pp. 2309–2315. (1997).

[76]Warner, E., Foulkes, W., Goodwin, P., et al. "Preva-lence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer", J. Natl Cancer Inst, Vol. 91, pp. 1241-1247. (1999).

[77]Weitzel, J. N., Lagos, V., Blazer, K. R., Nelson, R., Ricker, C., Herzog, J., McGuire, C. and Neuhausen, S. "Prevalence of BRCA mutations and founder effect in high-risk Hispanic families; Cancer Epidemiol", Biomarkers Prev., Vol. 14, pp. 1666–1671. (2005).

[78]Wooster, R., Bignell, G., Lancaster, J., et al. "Identification of the breast cancer susceptibility gene BRCA2",Nature, Vol. 378, pp. 789 –92. (1995).

[79]Zhi, X., Szabo, C., Chopin, S., et al. "BRCA1 and BRCA2 sequence variants in Chinese breast cancer families", Hum. Mutat., Vol. 20, pp. 474. (2002).

Website

[1]Breast Cancer Information Core Database. [http://www.nhgri. nih.gov/Intramural_research/Lab_transfer/Bic/] (last access 15.09.2012).